Compositions and methods for inhibiting expression of CD45 gene

US8912316B2 · kind B2 · utility

Assignees

• Alnylam Pharmaceuticals, Inc. · US
• The Government of the United States, as Respresented by the Secretary of the Army · US

Inventors

• Antonin de Fougerolles · Waterloo, BE
• Pamela Tan · Kulmbach, DE
• Anna Borodovsky · Cambridge, US
• Tatiana Novobrantseva · Cambridge, US
• Sina Bavari · Dillsburg, US
• Kelly Lyn Warfield · Adamstown, US

Key dates

• Filing date: Sep 12, 2012
• Grant date: Dec 16, 2014
• Expiry date: Sep 12, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/3515
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the CD45 gene.